Grace Halsey

The sudden appearance of "a black nail" can frighten a patient and should be investigated. Nail expert Boni Elewski, MD, shares 3 cases and the outcomes.

Susan C Taylor, MD, is internationally recognized for her expertise in dermatologic conditions in skin of color and spoke about avoiding photodamage at the Midwinter Clinical Derm Conference.

Established therapies for these common disorders don't always lead to optimal results; experts offer new evidence-based options that may help.

Systemic therapy for nail disorders, including biologics and JAK inhibitors, is gaining favor; learn more about early diagnosis and aggressive treatment from an expert.

From the revolutionary approval of dupilumab to the promise of potential disease modification with OX40 inhibitors, Golant provided a wide-ranging update of the treatment space.

How to treat lichenoid dermatoses, what to do when the Quant Gold is indeterminate, pocket-sized Wood lights, plus 9 more pearls from the experts.

Switching biologic treatment for patients with moderate to severe psoriasis, needn't be daunting, Vender said; he works through a tricky case that ended very well.

The ACIP of the CDC will meet on February 26 to vote on recommendations for appropriate incorporation of Penmenvy into the routine vaccination schedule.

Dermatology experts share pearls to help when biologics alone are not enough, when obesity is a comorbidity with psoriasis, and when isotype switching derails therapy.

JAK inhibitors are being used widely and successfully to treat alopecia areata, and Amy McMichaels, MD, showcased data and also discussed patient communication.

There really is no debate - it's all about individualizing treatment for the patient, but Drs Neal Bhatia and Raj Chovatiya went head to head at Midwinter Hawaii.

The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.

The dermatologic tips offered in this short slide show come from 4 renowned professionals and reflect their subspecialties.

Atopic dermatitis management will be the topic of a debate over treatment with biologics and JAK inhibitors and in a focused session on the role of IL-13 in the chronic skin disease.

The 2 analyses of data on fertility and infant mortality were conducted in the first 14 states to impose complete or 6-week bans after the Dobbs decision in June 2022.

The 2025 Winter Clinical Hawaii kicks off today with the first full day of educational sessions starting tomorrow, February 15 - here's what to look for.

More consistent use of evidence-based guidelines and individualized pain management for every patient lead the hopes Edward Mariano, MD, MAS has for the future.

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

Pooled data from the pivotal randomized clinical trials were consistent with prior outcomes supporting early occurrence and resolution of the most common TEAEs.

AAAAI 2025. Treatment response rates with daily use of the VIASKIN peanut patch increased from 39% at baseline to 73.3% at 60 months in youth aged 4 to 11 years.

Edward Mariano, MD, MAS, looks at the risk of acute pain transitioning to a chronic condition and how a new nonopioid for acute pain might work for the latter.

Fentanyl overdoses increasingly reveal combined use of stimulants including cocaine and methamphetamine, according to the 2025 update.

Topline data announced by Boehringer Ingelheim for the PDE4B inhibitor showed a statistically significant absolute change from baseline in FVC at week 52 vs placebo.

Multimodal pain management expert and researcher Mariano describes the NaV1.8 inhibitor as "working in concert" with nonopioid therapies, including nerve blocks.

An anesthesiologist and renowned investigator in use of nonopioids as part of multimodal pain management, Edward Mariano, MD, MAS, describes slow uptake in the field.

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

In letters to the FDA and Fox Broadcasting, PSM enumerated the laws abrogated and the potential harms of the ad being viewed by 200 million people on February 9, 2025.

Opioid prescribing has seen its extremes, from the 5th Vital Sign era in the aughts to the CDC restrictions of 2016. Mariano talks about the environment right now.